Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspt189dxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | JAN 02 | STN pricing information for 2008 now available |
| NEWS 3 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS 4 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS 5 | JAN 28 | MARPAT searching enhanced |
| NEWS 6 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS 7 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS 8 | JAN 28 | MEDLINE and LMEDLINE reloaded with enhancements |
| NEWS 9 | FEB 08 | STN Express, Version 8.3, now available |
| NEWS 10 | FEB 20 | PCI now available as a replacement to DPCI |
| NEWS 11 | FEB 25 | IFIREF reloaded with enhancements |
| NEWS 12 | FEB 25 | IMSPRODUCT reloaded with enhancements |
| NEWS 13 | FEB 29 | WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification |
| NEWS 14 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS 15 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS 16 | MAR 31 | CA/CAplus and CASREACT patent number format for U.S. applications updated |
| NEWS 17 | MAR 31 | LPCI now available as a replacement to LDPCI |
| NEWS 18 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS 19 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| NEWS 20 | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats |
| NEWS 21 | APR 28 | EMBASE Controlled Term thesaurus enhanced |
| NEWS 22 | APR 28 | IMSRESEARCH reloaded with enhancements |
| NEWS 23 | MAY 30 | INPAFAMDB now available on STN for patent family searching |
| NEWS 24 | MAY 30 | DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option |
| NEWS 25 | JUN 06 | EPFULL enhanced with 260,000 English abstracts |
| NEWS 26 | JUN 06 | KOREAPAT updated with 41,000 documents |
| NEWS 27 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications |
| NEWS 28 | JUN 19 | CAS REGISTRY includes selected substances from web-based collections |

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 03:54:26 ON 23 JUN 2008

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:54:44 ON 23 JUN 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s colostrum and filter? and steril? and inject? and cow and calf and filters and
micron?
  20 FILES SEARCHED...
  27 FILES SEARCHED...
  56 FILES SEARCHED...
        14   FILE USPATFULL
         3   FILE USPAT2
  67 FILES SEARCHED...

   2 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L1   QUE COLOSTRUM AND FILTER? AND STERIL? AND INJECT? AND COW AND CALF AND FIL
       TERS AND MICRON?

=> file uspatfull uspat2
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     3.90       4.11

FILE 'USPATFULL' ENTERED AT 03:58:10 ON 23 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 03:58:10 ON 23 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L2          17 L1

=> d l2 1-17

L2   ANSWER 1 OF 17  USPATFULL on STN
```

AN 2008:118417 USPATFULL
TI Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
IN Zeligs, Michael A., Boulder, CO, UNITED STATES
PI US 20080103114 A1 20080501
AI US 2005-322803 A1 20051230 (11)
PRAI US 2004-640301P 20041230 (60)
DT Utility
FS APPLICATION
LN.CNT 2652
INCL INCLM: 514/080.000
INCLS: 514/410.000; 514/414.000; 514/151.000
NCL NCLM: 514/080.000
NCLS: 514/410.000; 514/414.000; 514/151.000
IC IPCI A61K0031-675 [I,A]; A61K0031-655 [I,A]; A61K0031-407 [I,A]; A61K0031-405 [I,A]; A61K0031-403 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 17 USPATFULL on STN
AN 2007:224296 USPATFULL
TI Recombinant Neospora antigens and their uses
IN Conrad, Patricia A., Davis, CA, UNITED STATES
Barr, Bradd C., Davis, CA, UNITED STATES
Anderson, Mark L., Davis, CA, UNITED STATES
Sverlow, Karen W., Vacaville, CA, UNITED STATES
PA The Regents of the University of California, Oakland, CA, UNITED STATES, 94607-5200 (U.S. corporation)
PI US 20070196393 A1 20070823
AI US 2005-240049 A1 20050930 (11)
RLI Continuation of Ser. No. US 2004-899538, filed on 26 Jul 2004, GRANTED, Pat. No. US 7056501 Continuation of Ser. No. US 2001-957995, filed on 21 Sep 2001, GRANTED, Pat. No. US 6777192 Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, GRANTED, Pat. No. US 6376196 Continuation-in-part of Ser. No. US 1996-645951, filed on 10 May 1996, GRANTED, Pat. No. US 5889166 Continuation-in-part of Ser. No. US 1994-327516, filed on 20 Oct 1994, GRANTED, Pat. No. US 5707617 Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2600
INCL INCLM: 424/269.100
INCLS: 514/044.000; 435/006.000; 435/069.300; 435/258.100; 435/471.000; 530/350.000; 536/023.700; 530/388.600
NCL NCLM: 424/269.100
NCLS: 435/006.000; 435/069.300; 435/258.100; 435/471.000; 514/044.000; 530/350.000; 530/388.600; 536/023.700
IC IPCI A61K0039-00 [I,A]; C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12N0001-10 [I,A]; C12N0015-74 [I,A]; C07K0014-44 [I,A]; C07K0014-435 [I,C*]; C07K0016-20 [I,A]; C07K0016-18 [I,C*]
IPCR A61K0039-00 [I,C]; A61K0039-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-435 [I,C]; C07K0014-44 [I,A]; C07K0016-18 [I,C]; C07K0016-20 [I,A]; C12N0001-10 [I,C]; C12N0001-10 [I,A]; C12N0015-74 [I,C]; C12N0015-74 [I,A]; C12Q0001-68 [I,C]; C12Q0001-68 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 17 USPATFULL on STN
AN 2005:232998 USPATFULL
TI Ligands directed to the non-secretory component, non-stalk region of pIgR and methods of use thereof

IN Mostov, Keith E., San Francisco, CA, UNITED STATES
Chapin, Steven J., San Diego, CA, UNITED STATES
Richman-Eisenstat, Janice, Winnepeg, CANADA
PA The Regents of the University of California, Oakland, CA, UNITED STATES (U.S. corporation)
PI US 20050201932 A1 20050915
AI US 2005-38956 A1 20050119 (11)
RLI Division of Ser. No. US 2001-818247, filed on 26 Mar 2001, GRANTED, Pat. No. US 6855810
PRAI US 2000-192197P 20000327 (60)
US 2000-192198P 20000327 (60)
DT Utility
FS APPLICATION
LN.CNT 4424
INCL INCLM: 424/001.490
INCLS: 435/455.000; 424/178.100
NCL NCLM: 424/001.490
NCLS: 424/178.100; 435/455.000
IC [7]
ICM A61K051-00
ICS A61K039-395; C12N015-85
IPCI A61K0051-00 [ICM,7]; A61K0039-395 [ICS,7]; C12N0015-85 [ICS,7]
IPCR A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0016-18 [I,C*]; C07K0016-28 [I,A]; C12P0021-04 [I,C*]; C12P0021-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 17 USPATFULL on STN
AN 2005:4330 USPATFULL
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia, Davis, CA, UNITED STATES
Barr, Bradd C., Davis, CA, UNITED STATES
Anderson, Mark L., Davis, CA, UNITED STATES
Sverlow, Karen W., Vacaville, CA, UNITED STATES
PA The Regents of the University of California, Oakland, CA (U.S. corporation)
PI US 20050003433 A1 20050106
US 7056501 B2 20060606
AI US 2004-899538 A1 20040726 (10)
RLI Continuation of Ser. No. US 2001-957995, filed on 21 Sep 2001, GRANTED, Pat. No. US 6777192 Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, GRANTED, Pat. No. US 6376196 Continuation-in-part of Ser. No. US 1996-645951, filed on 10 May 1996, GRANTED, Pat. No. US 5889166 Continuation-in-part of Ser. No. US 1994-327516, filed on 20 Oct 1994, GRANTED, Pat. No. US 5707617 Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2616
INCL INCLM: 435/006.000
INCLS: 435/007.220; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.700
NCL NCLM: 424/093.100; 435/006.000
NCLS: 424/093.700; 435/007.220; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.700
IC [7]
ICM C12Q001-68
ICS G01N033-53; G01N033-569; C07H021-04; C07K014-44
IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-569 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-44 [ICS,7]; C07K0014-435 [ICS,7,C*]
IPCI-2 A01N0063-00 [I,A]; A01N0065-00 [I,A]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-00 [N,C*];

A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A];
C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-569 [I,C*];
G01N0033-569 [I,A]; A01N0063-00 [I,A]; A01N0063-00 [I,C];
A01N0065-00 [I,C]; A01N0065-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 17 USPATFULL on STN
AN 2004:85099 USPATFULL
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia A., Davis, CA, United States
Barr, Bradd C., Davis, CA, United States
Anderson, Mark L., Davis, CA, United States
Sverlow, Karen W., Vacaville, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6716423 B1 20040406
AI US 2000-612858 20000710 (9)
RLI Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, now patented, Pat. No. US 6376196 Continuation-in-part of Ser. No. US 1996-645951, filed on 10 May 1996, now patented, Pat. No. US 5889166, issued on 30 Mar 1999 Continuation-in-part of Ser. No. US 1994-327516, filed on 20 Oct 1994, now patented, Pat. No. US 5707617, issued on 13 Jan 1998 Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 2637
INCL INCLM: 424/093.100
INCLS: 424/093.700; 424/184.100; 424/234.100
NCL NCLM: 424/093.100
NCLS: 424/093.700; 424/184.100; 424/234.100
IC [7]
ICM A61K039-00
ICS A61K039-38; A61K039-02; A01N063-00; A01N065-00
IPCI A61K0039-00 [ICM,7]; A61K0039-38 [ICS,7]; A61K0039-02 [ICS,7]; A01N0063-00 [ICS,7]; A01N0065-00 [ICS,7]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-569 [I,C*]; G01N0033-569 [I,A]
EXF 424/184.1; 424/93.1; 424/93.7; 424/234.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 17 USPATFULL on STN
AN 2002:295323 USPATFULL
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia C., Davis, CA, UNITED STATES
Barr, Bradd C., Davis, CA, UNITED STATES
Anderson, Mark L., Davis, CA, UNITED STATES
Sverlow, Karen W., Vacaville, CA, UNITED STATES
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA, UNITED STATES, 94607-5200 (U.S. corporation)
PI US 20020165373 A1 20021107
US 6777192 B2 20040817
AI US 2001-957995 A1 20010921 (9)
RLI Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, GRANTED, Pat. No. US 6376196 Continuation of Ser. No. US 1996-645951, filed on 10 May 1996, GRANTED, Pat. No. US 5889166 Continuation of Ser. No. US 1994-327516, filed on 20 Oct 1994, GRANTED, Pat. No. US 5707617 Continuation of Ser. No. US 1994-215858, filed on 21 Mar 1994, ABANDONED
DT Utility
FS APPLICATION

```
LN.CNT 2670
INCL    INCLM: 536/023.100
NCL     NCLM:  435/007.100; 536/023.100
        NCLS:  435/007.210; 435/007.920
IC      [7]
        ICM    C07H021-02
        ICS    C07H021-04
        IPCI   C07H0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
        IPCI-2 G01N0033-53 [ICM,7]; G01N0033-567 [ICS,7]; G01N0033-537 [ICS,7];
               G01N0033-536 [ICS,7,C*]
        IPCR   A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-00 [N,C*];
               A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A];
               C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-569 [I,C*];
               G01N0033-569 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 7 OF 17  USPATFULL on STN
AN      2002:191592  USPATFULL
TI      Ligands directed to the non-secretory component, non-stalk region of
        pIgR and methods of use thereof
IN      Mostov, Keith E., San Francisco, CA, UNITED STATES
        Chapin, Steven J., San Diego, CA, UNITED STATES
        Richman-Eisenstat, Janice, Winnepeg, CANADA
PI      US 20020102657      A1  20020801
        US 6855810          B2  20050215
AI      US 2001-818247      A1  20010326 (9)
PRAI    US 2000-192197P     20000327 (60)
        US 2000-192198P     20000327 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4036
INCL    INCLM: 435/070.210
        INCLS: 530/388.220; 435/326.000
NCL     NCLM:  530/387.900; 435/070.210
        NCLS:  530/387.100; 530/387.300; 530/387.500; 530/388.100; 530/389.100;
               530/391.700; 435/326.000; 530/388.220
IC      [7]
        ICM    C12P021-04
        ICS    C12N005-06; C07K016-28
        IPCI   C12P0021-04 [ICM,7]; C12N0005-06 [ICS,7]; C07K0016-28 [ICS,7];
               C07K0016-18 [ICS,7,C*]
        IPCI-2 C07K0016-00 [ICM,7]
        IPCR   A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0016-18 [I,C*];
               C07K0016-28 [I,A]; C12P0021-04 [I,C*]; C12P0021-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 8 OF 17  USPATFULL on STN
AN      2002:191481  USPATFULL
TI      Nucleic acid encoding an avian E.coli iss polypeptide and methods of use
IN      Nolan, Lisa K., Fargo, ND, UNITED STATES
        Horne, Shelley M., Fargo, ND, UNITED STATES
PI      US 20020102546      A1  20020801
AI      US 2000-738599      A1  20001215 (9)
RLI     Continuation-in-part of Ser. No. US 1999-282352, filed on 31 Mar 1999,
        GRANTED, Pat. No. US 6187321 Division of Ser. No. US 1998-23221, filed
        on 12 Feb 1998, GRANTED, Pat. No. US 6087128
DT      Utility
FS      APPLICATION
LN.CNT 2577
INCL    INCLM: 435/006.000
        INCLS: 435/091.200
NCL     NCLM:  435/006.000
```

NCLS: 435/091.200
IC [7]
ICM C12Q001-68
ICS C12P019-34
IPCI C12Q0001-68 [ICM,7]; C12P0019-34 [ICS,7]; C12P0019-00 [ICS,7,C*]
IPCR C07K0014-195 [I,C*]; C07K0014-245 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 17 USPATFULL on STN
AN 2002:88219 USPATFULL
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia, Woodland, CA, United States
Louie, Kitland, San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6376196 B1 20020423
AI US 1999-281766 19990330 (9)
RLI Continuation-in-part of Ser. No. US 1996-645951, filed on 10 May 1996, now patented, Pat. No. US 5889166
DT Utility
FS GRANTED
LN.CNT 2125
INCL INCLM: 435/007.100
INCLS: 435/007.210; 435/007.920
NCL NCLM: 435/007.100
NCLS: 435/007.210; 435/007.920
IC [7]
ICM G01N033-53
ICS G01N033-567; G01N033-537
IPCI G01N0033-53 [ICM,7]; G01N0033-567 [ICS,7]; G01N0033-537 [ICS,7]; G01N0033-536 [ICS,7,C*]
IPCR C12N0015-09 [I,C*]; C12N0015-09 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-002 [I,C*]; A61K0039-002 [I,A]; A61P0033-00 [I,C*]; A61P0033-00 [I,A]; A61P0033-02 [I,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]; C12N0015-00 [I,C*]; C12N0015-00 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; C12R0001-90 [N,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-569 [I,C*]; G01N0033-569 [I,A]
EXF 424/184.1; 530/350; 435/7.1; 435/7.92; 435/7.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 17 USPATFULL on STN
AN 2000:15629 USPATFULL
TI Morphogen-enriched dietary composition
IN Kuberasampath, Thangavel, Medway, MA, United States
Cohen, Charles M., Medway, MA, United States
Rueger, David C., Hopkinton, MA, United States
Oppermann, Hermann, Medway, MA, United States
Pang, Roy H. L., Etna, NH, United States
PA Creative BioMolecules, Inc., Boston, MA, United States (U.S. corporation)
PI US 6022853 20000208
AI US 1994-278730 19940720 (8)
RLI Continuation of Ser. No. US 1992-946235, filed on 16 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned Ser. No. Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned Ser. No. Ser. No. US 1992-938336, filed on 28 Aug 1992, now abandoned Ser. No. Ser. No. US 1992-938337, filed on 28 Aug 1992, now abandoned And Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned , said Ser. No. US 922813 which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991,

now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 923780 which is a continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 667274 , said Ser. No. US 938336 which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 667274 , said Ser. No. US 938337 which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 667274 , said Ser. No. US 752764 which is a continuation-in-part of Ser. No. US 667274

DT Utility
FS Granted
LN.CNT 3692
INCL INCLM: 514/012.000
INCLS: 514/002.000; 424/439.000; 424/464.000
NCL NCLM: 514/012.000
NCLS: 424/439.000; 424/464.000; 514/002.000
IC [6]
ICM A61K038-18
IPCI A61K0038-18 [ICM,6]
IPCR A01N0001-02 [I,C*]; A01N0001-02 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0006-00 [I,C*]; A61K0006-00 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61L0027-00 [I,C*]; A61L0027-22 [I,A]; A61L0027-24 [I,A]; C07K0014-435 [I,C*]; C07K0014-51 [I,A]; C07K0016-18 [I,C*]; C07K0016-22 [I,A]
EXF 514/12; 424/439; 424/464; 426/657; 426/800; 426/801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 17 USPATFULL on STN
AN 1999:40580 USPATFULL
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia A., Davis, CA, United States
Barr, Bradd C., Davis, CA, United States
Anderson, Mark L., Davis, CA, United States
Sverlow, Karen W., Vacaville, CA, United States
Louie, Kitland, Davis, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5889166 19990330
AI US 1996-645951 19960510 (8)
DT Utility
FS Granted
LN.CNT 1991
INCL INCLM: 536/023.100
INCLS: 530/300.000; 530/350.000; 530/371.000
NCL NCLM: 536/023.100
NCLS: 530/300.000; 530/350.000; 530/371.000
IC [6]
ICM C07H021-02
ICS A61K038-00; C07K001-00
IPCI C07H0021-02 [ICM,6]; C07H0021-00 [ICM,6,C*]; A61K0038-00 [ICS,6]; C07K0001-00 [ICS,6]
IPCR C12N0015-09 [I,C*]; C12N0015-09 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-002 [I,C*]; A61K0039-002 [I,A]; A61P0033-00 [I,C*]; A61P0033-00 [I,A]; A61P0033-02 [I,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]; C12N0015-00 [I,C*]; C12N0015-00 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; C12R0001-90 [N,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-569 [I,C*]; G01N0033-569 [I,A]
EXF 536/23.1; 530/300; 530/350; 530/371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 17 USPATFULL on STN
AN 1998:4224 USPATFULL
TI Bovine neospora isolates
IN Conrad, Patricia A., Davis, CA, United States
Barr, Bradd C., Davis, CA, United States
Anderson, Mark L., Davis, CA, United States
Sverlow, Karen W., Vacaville, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5707617 19980113
AI US 1994-327516 19941020 (8)
RLI Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1673
INCL INCLM: 424/093.100
INCLS: 435/258.100
NCL NCLM: 424/093.100
NCLS: 435/258.100
IC [6]
ICM C12N001-10
IPCI C12N0001-10 [ICM,6]
IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]
EXF 424/93.1; 435/258.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 17 USPATFULL on STN
AN 96:77558 USPATFULL
TI Immunogenic anaplasma marginale surface antigens, compositions, and methods of use
IN McGuire, Travis C., SW. 920 Crestview, Pullman, WA, United States 99163
Palmer, Guy H., NW. 335 Dillon, Pullman, WA, United States 99163
Barbet, Anthony F., 31 SW. 21st Rd., Archer, FL, United States 32618
Davis, William C., NW. 300 Yates, Pullman, WA, United States 99163
PI US 5549898 19960827
AI US 1994-228180 19940415 (8)
RLI Continuation of Ser. No. US 1993-79971, filed on 18 Jun 1993, now abandoned which is a continuation of Ser. No. US 1992-875554, filed on 27 Apr 1992, now abandoned which is a continuation of Ser. No. US 1989-335178, filed on 6 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-253143, filed on 4 Oct 1988, now abandoned Ser. No. Ser. No. US 1988-245855, filed on 16 Sep 1988, now abandoned And Ser. No. US 1988-141505, filed on 7 Jan 1988, now abandoned which is a continuation of Ser. No. US 1985-761178, filed on 3 Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-715528, filed on 25 Mar 1985, now abandoned
DT Utility
FS Granted
LN.CNT 2189
INCL INCLM: 424/269.100
INCLS: 424/265.100; 424/266.100; 424/270.100
NCL NCLM: 424/269.100
NCLS: 424/265.100; 424/266.100; 424/270.100
IC [6]
ICM A61K039-00
ICS A61K039-002; A61K039-005; A61K039-018
IPCI A61K0039-00 [ICM,6]; A61K0039-002 [ICS,6]; A61K0039-005 [ICS,6]; A61K0039-018 [ICS,6]; A61K0039-002 [ICS,6,C*]

IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-195 [I,C*]; C07K0014-29 [I,A]; C07K0016-12 [I,C*]; C07K0016-12 [I,A]
EXF 424/93.1; 424/184.1; 424/190.1; 424/269.1; 424/184.1; 424/265.1; 424/266.1; 424/270.1; 424/269.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 17 USPATFULL on STN
AN 92:27316 USPATFULL
TI Method of producing remedies and products of the method
IN Collins, Robert A., 22 6th Ave. NE., Waukon, IA, United States 52172
PI US 5102669 19920407
AI US 1989-318069 19890221 (7)
RLI Continuation-in-part of Ser. No. US 1987-86539, filed on 18 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1984-609277, filed on 11 May 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-528881, filed on 2 Sep 1983, now abandoned
DT Utility
FS Granted
LN.CNT 674
INCL INCLM: 424/535.000
INCLS: 424/085.800; 424/086.000; 424/087.000
NCL NCLM: 424/535.000
IC [5]
ICM A61K035-20
IPCI A61K0035-20 [ICM,5]
IPCR A61K0035-12 [I,C*]; A61K0035-12 [I,A]
EXF 424/85; 424/87; 424/95; 424/105; 424/535; 424/85.8; 424/86

L2 ANSWER 15 OF 17 USPAT2 on STN
AN 2005:4330 USPAT2
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia A., Davis, CA, UNITED STATES
Barr, Bradd C., Davis, CA, UNITED STATES
Anderson, Mark L., Davis, CA, UNITED STATES
Sverlow, Karen W., Vacaville, CA, UNITED STATES
PA The Regent of the University of California, Oakland, CA, UNITED STATES (U.S. corporation)
PI US 7056501 B2 20060606
AI US 2004-899538 20040726 (10)
RLI Continuation of Ser. No. US 2001-957995, filed on 21 Sep 2001, Pat. No. US 6777192 Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, Pat. No. US 6376196 Continuation-in-part of Ser. No. US 1996-645951, filed on 10 May 1996, Pat. No. US 5889166 Continuation-in-part of Ser. No. US 1994-327516, filed on 20 Oct 1994, Pat. No. US 5707617 Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, ABANDONED
DT Utility
FS GRANTED
LN.CNT 2638
INCL INCLM: 424/093.100
INCLS: 424/093.700
NCL NCLM: 424/093.100; 435/006.000
NCLS: 424/093.700; 435/007.220; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.700
IC IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-569 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-44 [ICS,7]; C07K0014-435 [ICS,7,C*]
IPCI-2 A01N0063-00 [I,A]; A01N0065-00 [I,A]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-569 [I,C*];

G01N0033-569 [I,A]; A01N0063-00 [I,A]; A01N0063-00 [I,C];
A01N0065-00 [I,C]; A01N0065-00 [I,A]
EXF 424/93.1; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 17 USPAT2 on STN
AN 2002:295323 USPAT2
TI Recombinant neospora antigens and their uses
IN Conrad, Patricia A., Davis, CA, United States
Barr, Bradd C., Davis, CA, United States
Anderson, Mark L., Davis, CA, United States
Sverlow, Karen W., Vacaville, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6777192 B2 20040817
AI US 2001-957995 20010921 (9)
RLI Continuation of Ser. No. US 1999-281766, filed on 30 Mar 1999, now patented, Pat. No. US 6376196 Continuation-in-part of Ser. No. US 1996-645551, filed on 10 May 1996, now patented, Pat. No. US 5889166 Continuation-in-part of Ser. No. US 1994-327516, filed on 20 Oct 1994, now patented, Pat. No. US 5707617 Continuation-in-part of Ser. No. US 1994-215858, filed on 21 Mar 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 2690
INCL INCLM: 435/007.100
INCLS: 435/007.210; 435/007.920
NCL NCLM: 435/007.100; 536/023.100
NCLS: 435/007.210; 435/007.920
IC [7]
ICM G01N033-53
ICS G01N033-567; G01N033-537
IPCI C07H0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
IPCI-2 G01N0033-53 [ICM,7]; G01N0033-567 [ICS,7]; G01N0033-537 [ICS,7]; G01N0033-536 [ICS,7,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-44 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-569 [I,C*]; G01N0033-569 [I,A]
EXF 424/184.1; 435/7.1; 435/7.21; 435/7.92; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 17 USPAT2 on STN
AN 2002:191592 USPAT2
TI Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof
IN Mostov, Keith E., San Francisco, CA, United States
Chapin, Steven J., San Diego, CA, United States
Richman-Eisenstat, Janice, Winnepeg, CANADA
PA The Regents of the university of California, Oakland, CA, United States (U.S. corporation)
PI US 6855810 B2 20050215
AI US 2001-818247 20010326 (9)
PRAI US 2000-192197P 20000327 (60)
US 2000-192198P 20000327 (60)
DT Utility
FS GRANTED
LN.CNT 4362
INCL INCLM: 530/387.900
INCLS: 530/387.100; 530/387.300; 530/387.500; 530/388.100; 530/389.100; 530/391.700
NCL NCLM: 530/387.900; 435/070.210

```
      NCLS:  530/387.100; 530/387.300; 530/387.500; 530/388.100; 530/389.100;
             530/391.700; 435/326.000; 530/388.220
IC    [7]
      ICM    C07K016-00
      IPCI   C12P0021-04 [ICM,7]; C12N0005-06 [ICS,7]; C07K0016-28 [ICS,7];
             C07K0016-18 [ICS,7,C*]
      IPCI-2 C07K0016-00 [ICM,7]
      IPCR   A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0016-18 [I,C*];
             C07K0016-28 [I,A]; C12P0021-04 [I,C*]; C12P0021-04 [I,A]
EXF   530/387.1; 530/387.3; 530/387.5; 530/387.9; 530/388.1; 530/389.1;
      530/391.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> index bioscienced l2 l4
'BIOSCIENCED' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):d
'D' IS AN AMBIGUOUS FILE NAME
 DDFB          - Derwent Drug File, Backfile 1964 - 1982
 DDFU          - Derwent Drug File from 1983 - present
 DETHERM       - DETHERM-DECHEMA thermophysical property database
 DGENE         - Derwent Geneseq Database 1981 - present
 DISSABS       - Dissertation Abstracts from 1861 to present
 DJSMDS        - Derwent Reaction Search Service DJSM (Subscribers)
 DJSMONLINE    - Derwent Reaction Search Service DJSM
 DKF           - The German Automotive Engineering Database 1974-date
 DRUGB         - Derwent Drug File, Backfile 1964 - 1982 (Subscribers)
 DRUGMONOG     - IMS Product Monographs (Approved Pharm. Industry Users
 DRUGMONOG2    - IMS Product Monographs
 DRUGU         - Derwent Drug File from 1983-present (Subscribers)
ENTER A FILE NAME OR (IGNORE):.
'L4' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):.
'14' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):quite
'QUITE' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):i
'I' IS AN AMBIGUOUS REFERENCE
 IMSBASES          - IMS HEALTH Database Cluster
 ICONDA            - International Construction Database from 1976-present
 ICSD              - ICSD - Inorganic Crystal Structure Data File
 IFICDB            - The IFI Comprehensive Database from 1950-present
 IFICLS            - The IFI Current Patent Legal Status Database
 IFIPAT            - The IFI Patent Database from 1950-present
 IFIREF            - The IFI Uniterm and U.S. Class Reference File
 IFIUDB            - The IFI Uniterm Database from 1950-present
 IMSCOPROFILE      - IMS Company Profiles 1995-present
 IMSCOSEARCH       - IMS Company Search
 IMSDRUGNEWS       - IMS Drug News 1991-present
 IMSPATENTS        - IMS LifeCycle, Patent Focus with Patent Family Data
 IMSPRODUCT        - IMS LifeCycle, New Product Focus from 1982-present
 IMSRESEARCH       - IMS LifeCycle, R&D Focus 1977-present
 INFODATA          - Information Science and Work from 1976 to present
 INIS              - International Nuclear Information System  1970-present
 INPADOCDB         - The Intern. Patent Documentation Database 1836-pres.
 INPAFAMDB         - International Patent Family Database 1836-pres.
 INSPEC            - INSPEC file from 1898 - present
 INSPHYS           - INSPHYS - Inspec Phys Supplement Backfile (1979 - 1994
 IPA               - International Pharmaceutical Abstracts 1970-present
ENTER A FILE OR CLUSTER NAME (IGNORE):.
AT LEAST TWO FILES ARE NEEDED FOR STNINDEX
SESSION CONTINUES IN THE PREVIOUS FILE ENVIRONMENT
```

To see a list of files and clusters that may be used in the INDEX command, enter HELP FILE NAMES or HELP CLUSTER NAMES at an arrow prompt. Only the learning files and NBSFLUIDS may not be used in STNINDEX.

```
=> d hist

     (FILE 'HOME' ENTERED AT 03:54:26 ON 23 JUN 2008)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:54:44 ON 23 JUN 2008
               SEA COLOSTRUM AND FILTER? AND STERIL? AND INJECT? AND COW AND C
               ---------
              14   FILE USPATFULL
               3   FILE USPAT2
L1             QUE COLOSTRUM AND FILTER? AND STERIL? AND INJECT? AND COW AND C
               ---------

     FILE 'USPATFULL, USPAT2' ENTERED AT 03:58:10 ON 23 JUN 2008
L2          17 S L1

=> d l2 14

L2   ANSWER 14 OF 17  USPATFULL on STN
AN     92:27316  USPATFULL
TI     Method of producing remedies and products of the method
IN     Collins, Robert A., 22 6th Ave. NE., Waukon, IA, United States  52172
PI     US 5102669                19920407
AI     US 1989-318069            19890221 (7)
RLI    Continuation-in-part of Ser. No. US 1987-86539, filed on 18 Aug 1987,
       now abandoned which is a continuation-in-part of Ser. No. US
       1984-609277, filed on 11 May 1984, now abandoned which is a
       continuation-in-part of Ser. No. US 1983-528881, filed on 2 Sep 1983,
       now abandoned
DT     Utility
FS     Granted
LN.CNT 674
INCL   INCLM: 424/535.000
       INCLS: 424/085.800; 424/086.000; 424/087.000
NCL    NCLM:  424/535.000
IC     [5]
       ICM    A61K035-20
       IPCI   A61K0035-20 [ICM,5]
       IPCR   A61K0035-12 [I,C*]; A61K0035-12 [I,A]
EXF    424/85; 424/87; 424/95; 424/105; 424/535; 424/85.8; 424/86


=> d l2 14 ab

L2   ANSWER 14 OF 17  USPATFULL on STN
AB     A method of converting allergenic substances which may have medicinal
       value into a new, safe and effective non-toxic and novel product having
       utility as a homeopathic remedy. This invention contemplates converting
       toxic substances into useful medicaments by a process involving the
       mammary glands of animals.


=> d l2 14 kwic

L2   ANSWER 14 OF 17  USPATFULL on STN
```

SUMM . . . a minute fraction of the original crude substance used to produce the first mother. This product has been in effect filtered through the udder of an ungulate in this process of producing a homeopathic-like product. This process and product are not. . .

DETD . . . purified high lactose whey can be produced using a high speed continuous centrifuge that will remove all particles over 0.4 micron size. This high lactose whey is preferably then sterilized by passing it through a 0.2 micron sterilizing filter.

DETD . . . practice of this invention: infusing the first mother into the cistern through the orifice of the teat canal, using a sterile 10 cc syringe equipped with a blunt cannula; or, alternatively, injecting the side of the udder using a 10 cc sterile syringe equipped with a needle of suitable length. The infusion method has been found to be more feasible for repeated doses but requires more care to maintain sterility of equipment.

DETD A satisfactory dose of the first mother inserted into the udder of each cow, or other mammal, has been found to comprise 10 cc per quarter of a sterile suspension of a specific allergenic extract having about 3260 P.N.U. (Protein Nitrogen Units) per cc. Allergenic extracts are a commercially. . .

DETD . . . dose of the solution of the first mother, prepared as outlined above, is preferably infused into each quarter of a cow, using asceptic techniques, two or three times at 7 to 12 day intervals prior to parturition. Lactating cows may be used but the use of dry cows has been found to be less upsetting to the cow.

DETD When dry cows are infused, the colostrum and first milk as it comes from the cow after parturition is saved and is used as a second mother for the preparation of a homeopathic product by accepted. . .

DETD . . . producing homeopathic remedies, a life-death challenge test is not used. With the method of the instant invention of utilizing the cow to produce a second mother for the production of a homeopathic product, a life-death challenge test is feasible.

DETD . . . known in the art. The vaccine was heat-killed, corrected to a density of McFarland 5, and bottled in 40 ml sterile serum bottles, capped with a sterile rubber stopper. A second calf Holstein heifer was health-checked by a veterinarian. This cow was infused with 5 ml of the above vaccine, intermammary, three times at weekly intervals just prior to parturition.

DETD When the cow calved, one gallon of colostrum was saved in a gallon jug market "A" and refrigerated, and one gallon of milk was saved in a gallon jug marked "C" and refrigerated. One ml colostrum from jug "A" was vigorously mixed with 9 ml sterile distilled water in a 20 ml test tube and capped with a sterile rubber stopper. This process was carried out in a sterile room under a Hepa filter. 1 ml of this dilution was mixed with 9 ml sterile distilled water and vigorously mixed by shaking and vortexing the fluid.

DETD 1 ml of this 2nd serial dilution was diluted with 9 ml sterile distilled water and vigorously mixed as above, in a 20 ml test tube. This 3rd serial dilution was then bottled in sterile 20 ml serum bottles, capped with a sterile rubber stopper and sealed with an aluminum crimped seal. This was marked A-3x. 1 ml colostrum from the jug marked "A" was serial diluted in the same manner described above for six serial dilutions. The sixth dilution was sterile bottled in 20 ml serum bottles using the technique described above. This bottle was marked A-6x.

DETD . . . carried out to 3 serial dilution in the same manner as above. The product of the 3rd dilution was then sterile bottled in 20 ml serum bottles, capped with a sterile rubber stopper and

sealed with an aluminum crimped seal. This bottle was marked C-3x.

DETD 1 ml milk from the jug marked "C" was diluted with 9 ml sterile distilled water in a 20 ml test tube, stoppered and vigorously mixed by shaking and vortexing. This process was carried. . . for a total of six serial dilutions. The product of the sixth serial dilution was then bottled in 20 ml sterile serum bottles, capped and sealed as above. This bottle was marked C-6x.

DETD The four products marked A-3x, A-6x, C-3x and C-6x were then tested on mice previously injected I.P. with a lethal challenge of pathogenic pseudomonas aurogenosa at the rate of 25+10.sup.6 per ml. Results were as follows:

DETD . . . Alive

| | | | Sick | Dead | |
|---|---|---|---|---|---|
| TEST 1 | | | | | |
| NON USED** | | | | | |
| | WATER | 25 + 10.sup.6 | 1 | 0 | 3 |
| NON USED | | | | | |
| | 2 mg eq. 390* | " | 4 | 0 | 0 |
| COLOSTRUM | | | | | |
| | A 3x | " | 2 | 0 | 2 |
| COLOSTRUM | | | | | |
| | A 6x | " | 3 | 0 | 1 |
| MILK | C 3x | " | 1 | 0 | 3 |
| MILK | C 6x | " | 3 | 0 | 1 |
| NON USED** | | | | | |
| | Water. . . | 1 | 0 | 0 | |
| TEST 2 | | | | | |
| NON USED** | | | | | |
| | WATER | 25 + 10.sup.6 | 1 | 0 | 3 |
| NON USED | | | | | |
| | 2 mg eq. 390* | " | 4 | 0 | 0 |
| COLOSTRUM | | | | | |
| | 1 cc A 3x | " | 3 | 0 | 1 |
| COLOSTRUM | | | | | |
| | .5 cc A 3x | " | 4 | 0 | 0 |
| COLOSTRUM | | | | | |
| | .25 cc A 3x | " | 4 | 0 | 0 |
| MILK | 1 cc C 3x | " | 3 | 0 | 1 |
| MILK | .5 cc C 3x | | | | |
| . . . | " | 3 | 0 | 1 | |
| NON USED** | | | | | |
| | WATER | 0 | 4 | 0 | 0 |

4 mice per group

*390 is our positive control

A Colostrum used as a raw material to produce the second mother

C Milk used as raw material to produce the second. . .

DETD Using sterile techniques, 60 cc of the above pseudomonas aurogenosa vaccine was diluted with 60 cc of sterile whey.

DETD The first mother was sterile bottled in these 40 cc vials equipped with sterile rubber sleeve stoppers and stored under refrigeration for later use in the production of a second mother. The 40 cc vial size was employed for convenience in later infusion into the udder of the cow, 10 cc per quarter.

DETD . . . this point 20 cc of the above solution was added to 20 cc of purified whey that had been previously filtered through a 0.2 micron filter to produce one animal infusion in the case of a cow, or two animal infusions for goats.

DETD An example of the method of producing the second mother involved use of a healthy cow carrying her second or later calf, about one month preparatum. The udder and teats are prepared and treated in the following manner:

DETD (3) Cover test opening (or point of injection if one chooses to go through the side of the udder) with a cotton swab previously soaked in a 70%. . .

DETD (4) Fill four 10 cc syringes with the previously prepared first mother, using a sterile syringe needle for withdrawal from the bottle;

DETD . . . introducing the substance into the udder via the teat canal, remove the needle from the syringe and replace with a sterile cannula;

DETD . . . contaminated by touching the side of the teat or the operator's fingers, it should be discarded and replaced with a sterile cannula.

DETD A separate syringe and sterile cannula should be used for each quarter. This procedure should be repeated two or three times at seven to ten. . . to parturition. At parturition, for the production of a high potency product of this invention, a few pounds of the colostrum and milk is saved in well-marked containers and frozen for storage. Prior to freezing the colostrum and milk is filtered through a 0.2 micron filter which filters out large molecules and antibodies. An 0.1 micron filter may be used which will filter out smaller molecules and antibodies. It is not necessary that the milk be filtered as long as some suitable means of separating out the larger molecules is used.

DETD 1cc of this colostrum or milk can now be used to produce a second mother by adding 1 cc of the colostrum or milk to 9 cc of water, or water and ethyl alcohol, to produce a 10% (10:1) liquid attenuation which. . .

DETD (2) infuse the cow with such first mother to product the second mother;

DETD First, in the establishment of a lethal dose, it was found that 25+10.sup.6 organisms of a specific pseudomonas injected I.P. would kill two out of three mice. All mice indicated were challenged with 25+10.sup.6 specific pseudomonas organisms I.P.

DETD The first test was performed to observe the effect of a 1 cc injected I.P. of a 3x and 6x homeopathic remedy prepared using one gram of colostrum or one gram of milk, to produce the second mother and then serially diluting and succusing 1 cc of the. . .

DETD . . . TREATMENT CHALLENGE Alive
Sick
Dead

---

TEST 1

| | | | | | |
|---|---|---|---|---|---|
| | WATER | 25 + 10.sup.6 | 1 | 0 | 3 |
| | 2 mg eq. 390 | " | 4 | 0 | 0 |
| COLOSTRUM | A 3x | " | 2 | 0 | 2 |
| COLOSTRUM | A 6x | " | 3 | 0 | 1 |
| MILK | C 3x | " | 1 | 0 | 3 |
| MILK | C 6x | " | 3 | 0 | 1 |
| | Water (one. . . mouse) | | | | |

| | | | | | |
|---|---|---|---|---|---|
| | | 0 | 1 | 0 | 0 |
| TEST 2 | | | | | |
| | WATER | 25 + 10.sup.6 | | | |
| | | | 1 | 0 | 3 |
| | 2 mg eq. 390 | | | | |
| | | " | 4 | 0 | 0 |
| COLOSTRUM | | | | | |
| | 1 cc A 3x | " | 3 | 0 | 1 |
| COLOSTRUM | | | | | |
| | .5 cc A 3x | | | | |
| | | " | 4 | 0 | 0 |
| COLOSTRUM | | | | | |
| | .25 cc A 3x | | | | |
| | | " | 4 | 0 | 0 |
| MILK | 1 cc C 3x | " | 3 | 0 | 1 |
| MILK | .5 cc C 3x | | | | |
| . . . | 1 | | | | |
| | WATER | 0 | 4 | 0 | 0 |

---

4 mice per group
390 is our positive control for protection of animal
A colostrum used to produce the second mother
C milk used to produce the second mother
Tests conducted at DerseSchroeder Laboratories, Madison,. . .

DETD . . . used in the preparation of vaccines. The vaccine was then bottled aseptically in 60 cc serum-type glass vials, capped with sterile rubber stoppers and sealed with aluminum seals. It was marked Staph-I for identification. A code number was also assigned.

DETD For the production of the second mother, a cow 3-4 weeks prepartum was selected. A visible health check was made by a veterinarian, along with a brucella and TB. . .

DETD Four sterile 5 cc syringe equipped with an 18 gauge hypodermic needle was each filled with the vaccine from the bottle marked Staph-1, previously prepared. The hypodermic needles were then disconnected from each syringe and replaced with a sterile plastic canulae. As each canulae was attached, the anulae end of the syringe was stored in an open sterilizing bag for protection. The cow was then infused, through the teat opening, using the prepared syringes.

DETD The infusion was repeated at seven-day intervals for a total of three infusions. Detailed records were maintained, including the cow identification, the vaccine dose, dates and times of infusion, date of calving and the initials of the person doing the. . .

DETD Preferably when the cow is calved, the cow was milked and the milk was filtered with a 0.1 micron filter to filter out antibodies. One gallon of this filtered colostrum and early milk was saved in a gallon plastic jug. The jug was tagged, using a waterproof tape, showing the date, vaccine code and the cow number or name. The identification, Staph-1, was also put on the jug, using a permanent magic marker. The jug with the Staph-1 colostrum was frozen for storage.

DETD . . . the Staph-1 product, detailed above, was employed to produce a product starting with each of the isolates listed above. Three 2nd-calf Holstein cows, all about one month prepartum, were selected. One for each of the three additional products to be produced.. .

DETD As these cows calved, one gallon of colostrum was saved in a plastic jug. The jug was tagged with the code assigned the isolate referenced and the cow number or name. The jug was then frozen for storage. When all three jugs were frozen, they were thawed, along. . .

DETD . . . end over end. The jar was coded with each of the four codes

used to identify each isolate and each cow used to produce the four individual components of this jar.

DETD From this point on, all work was carried out under a Hepa filter , using aseptic procedures, by gowned and masked technicians, wearing sterile rubber gloves.

DETD One ml of the product in the jaw with the four components was withdrawn using a sterile pipette. This was added to 9 ml sterile distilled water in a 20 ml sterile test tube, stoppered with a sterile rubber stopper. This ten-fold dilution was vigorously mixed by shaking and vortexing.

DETD One ml of this first serial dilution was then diluted with 9 ml sterile distilled water and thoroughly blended as above. This process was carried out for six serial dilutions.

DETD The product of the sixth serial dilution was bottled in 50 ml sterile serum type bottles, capped with a sterile rubber cap and sealed with an aluminum seal. Ten 50 cc bottles were then sent to the veterinarian doing the. . .

DETD

Problem cows in herd code DM-10
High Somatic Cell Count (SCC), March 1987

| Cow No. | SCC on March 5 | Treatment | SCC on March 20 |
|---|---|---|---|
| 66 | >1,000,000 | 2-4 5 cc MT on feed | <200,000 |
| 65 | ". . . | <200,000 | |
| 69 | " | " | <200,000 |
| 173 | " | " | <200,000 |
| 200 | " | " | <200,000 |
| 136 | " | " | <200,000 |
| 124 | " | " | <200,000 |
| 150 | " | " | <200,000 |

June 1987

| Cow No. | SCC on June 17 | Treatment | SCC on June 22 |
|---|---|---|---|
| 82 | >1,000,000 | 5 cc MT, 2-4 times | <200,000 |
| | | 12 hr interval. . . hr interval on feed | |
| 75 | " | 5 cc MT, 2-4 times | <200,000 |
| | | 12 hr interval on feed | |

Note: Only one cow, #60, repeated in the second list in June. The necessity of reducing a high cell count in a dairy herd. . .

DETD Three of the four jugs of colostrum produced for Example 1 above were removed from the freezer and thawed. 25 ml was transferred from the jug with. . .

DETD . . . blended by shaking. 1 ml of the product in this 6 oz glass jar was transferred to a 20 ml sterile test tube containing 9 ml sterile distilled water. This transfer was accomplished by the use of a sterile pipette. This test tube was stoppered with a sterile rubber stopper and vigorously mixed by shaking and vortexing.

DETD 1 ml of this first 10-fold dilution was aseptically transferred to a second 20 ml sterile test tube containing 9 ml sterile distilled water. This serial dilution was mixed by vigorously shaking and vortexing. This process was carried to the 6th serial. . .

DETD The 6th dilution was sterile bottled in 60 cc serum bottles. The label, serial number and code were referenced to the original culture.

DETD _____
RESULTS -

| Cow Identification | Condition | Amount | Treatment Number | Hours to Return to Normal |
|---|---|---|---|---|
| #11RN | Clincal | 10 cc IU* | 2 | 36 |
| #33RN | Clincal | 10 cc IU | 2. . . | without the use of antibotics. This is due to the milk throwaway |

required when antibiotics were given a lactating dairy cow.
*Inter udder

CLM What is claimed is:
. . . the udder and separating out and disposing of larger molecules including antibodies from the second mother which are approximately 0.2 micron and larger; and E. serially diluting said second mother to 10.sup.3 to 10.sup.30.

CLM What is claimed is:
3. The process of claim 1, wherein said combination is introduced into the udder of a cow or goat, to therein effect said conversion of the raw product into a sarcode suitable for use in the production. . .

CLM What is claimed is:
. . . homeopathic characteristics of the first mother, and not depending on antibodies; and C. removing the second mother from the udder, filtering out larger molecules including antibodies from the second mother with approximately a 0.1 micron filter and serially diluting said second mother.

CLM What is claimed is:
. . . depending on antibodies, separating out and disposing of larger molecules including antibodies from the lacteal fluid which are approximately 0.1 micron and larger, and serially diluting said second mother.

CLM What is claimed is:
. . . homeopathic characteristics of the first mother and not including antibodies; D. collecting lacteal secretion; E. establishing the desired potency; F. filtering out larger molecules including antibodies from lacteal secretion with approximately a 0.1 micron filter; G. and serially diluting said second mother.

CLM What is claimed is:
. . . homeopathic characteristics of the first mother and not including antibodies; D. collecting lacteal secretion; E. establishing the desired potency; F. filtering out larger molecules including antibodies from lacteal secretion with approximately a 0.1 micron filter; G. and serially diluting said second mother.

=> d hist

(FILE 'HOME' ENTERED AT 03:54:26 ON 23 JUN 2008)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

```
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:54:44 ON 23 JUN 2008
                SEA COLOSTRUM AND FILTER? AND STERIL? AND INJECT? AND COW AND C
                ---------
               14   FILE USPATFULL
                3   FILE USPAT2
L1               QUE COLOSTRUM AND FILTER? AND STERIL? AND INJECT? AND COW AND C
                 ---------

     FILE 'USPATFULL, USPAT2' ENTERED AT 03:58:10 ON 23 JUN 2008
L2           17 S L1

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     30.45      34.56

STN INTERNATIONAL LOGOFF AT 04:02:23 ON 23 JUN 2008
```